Development of a Flare Instrument for Use in Psoriatic Disease: A Report from the 2015 GRAPPA Annual Meeting.
Identifieur interne : 000148 ( PubMed/Corpus ); précédent : 000147; suivant : 000149Development of a Flare Instrument for Use in Psoriatic Disease: A Report from the 2015 GRAPPA Annual Meeting.
Auteurs : Anna R. Moverley ; Robin Waxman ; Maarten De Wit ; Andrew Parkinson ; Willemina Campbell ; Melanie Brooke ; Laure Gossec ; Philip S. HelliwellSource :
- The Journal of rheumatology [ 0315-162X ] ; 2016.
Abstract
The objective of this Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) initiative is to develop a questionnaire to determine the presence of a flare of disease activity in psoriatic disease (PsD), for use in clinical care and research settings.
DOI: 10.3899/jrheum.160118
PubMed: 27134273
Links to Exploration step
pubmed:27134273Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of a Flare Instrument for Use in Psoriatic Disease: A Report from the 2015 GRAPPA Annual Meeting.</title><author><name sortKey="Moverley, Anna R" sort="Moverley, Anna R" uniqKey="Moverley A" first="Anna R" last="Moverley">Anna R. Moverley</name><affiliation><nlm:affiliation>From the Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK; VU Medical Centre, Amsterdam, The Netherlands; Toronto Western Hospital, Toronto, Ontario, Canada; PsAZZ Psoriatic Arthritis Support Group, Bath, UK; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.A.R. Moverley, MRCP, Research Fellow, Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; R. Waxman, MPH, Research Coordinator, Leeds Institute of Rheumatic and Musculoskeletal Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; A. Parkinson, Patient Research Partner; W. Campbell, BEd, LLB, Patient Research Partner, Toronto Western Hospital; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust.</nlm:affiliation></affiliation></author><author><name sortKey="Waxman, Robin" sort="Waxman, Robin" uniqKey="Waxman R" first="Robin" last="Waxman">Robin Waxman</name><affiliation><nlm:affiliation>From the Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK; VU Medical Centre, Amsterdam, The Netherlands; Toronto Western Hospital, Toronto, Ontario, Canada; PsAZZ Psoriatic Arthritis Support Group, Bath, UK; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.A.R. Moverley, MRCP, Research Fellow, Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; R. Waxman, MPH, Research Coordinator, Leeds Institute of Rheumatic and Musculoskeletal Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; A. Parkinson, Patient Research Partner; W. Campbell, BEd, LLB, Patient Research Partner, Toronto Western Hospital; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust.</nlm:affiliation></affiliation></author><author><name sortKey="De Wit, Maarten" sort="De Wit, Maarten" uniqKey="De Wit M" first="Maarten" last="De Wit">Maarten De Wit</name><affiliation><nlm:affiliation>From the Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK; VU Medical Centre, Amsterdam, The Netherlands; Toronto Western Hospital, Toronto, Ontario, Canada; PsAZZ Psoriatic Arthritis Support Group, Bath, UK; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.A.R. Moverley, MRCP, Research Fellow, Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; R. Waxman, MPH, Research Coordinator, Leeds Institute of Rheumatic and Musculoskeletal Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; A. Parkinson, Patient Research Partner; W. Campbell, BEd, LLB, Patient Research Partner, Toronto Western Hospital; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust.</nlm:affiliation></affiliation></author><author><name sortKey="Parkinson, Andrew" sort="Parkinson, Andrew" uniqKey="Parkinson A" first="Andrew" last="Parkinson">Andrew Parkinson</name><affiliation><nlm:affiliation>From the Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK; VU Medical Centre, Amsterdam, The Netherlands; Toronto Western Hospital, Toronto, Ontario, Canada; PsAZZ Psoriatic Arthritis Support Group, Bath, UK; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.A.R. Moverley, MRCP, Research Fellow, Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; R. Waxman, MPH, Research Coordinator, Leeds Institute of Rheumatic and Musculoskeletal Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; A. Parkinson, Patient Research Partner; W. Campbell, BEd, LLB, Patient Research Partner, Toronto Western Hospital; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust.</nlm:affiliation></affiliation></author><author><name sortKey="Campbell, Willemina" sort="Campbell, Willemina" uniqKey="Campbell W" first="Willemina" last="Campbell">Willemina Campbell</name><affiliation><nlm:affiliation>From the Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK; VU Medical Centre, Amsterdam, The Netherlands; Toronto Western Hospital, Toronto, Ontario, Canada; PsAZZ Psoriatic Arthritis Support Group, Bath, UK; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.A.R. Moverley, MRCP, Research Fellow, Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; R. Waxman, MPH, Research Coordinator, Leeds Institute of Rheumatic and Musculoskeletal Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; A. Parkinson, Patient Research Partner; W. Campbell, BEd, LLB, Patient Research Partner, Toronto Western Hospital; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust.</nlm:affiliation></affiliation></author><author><name sortKey="Brooke, Melanie" sort="Brooke, Melanie" uniqKey="Brooke M" first="Melanie" last="Brooke">Melanie Brooke</name><affiliation><nlm:affiliation>From the Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK; VU Medical Centre, Amsterdam, The Netherlands; Toronto Western Hospital, Toronto, Ontario, Canada; PsAZZ Psoriatic Arthritis Support Group, Bath, UK; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.A.R. Moverley, MRCP, Research Fellow, Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; R. Waxman, MPH, Research Coordinator, Leeds Institute of Rheumatic and Musculoskeletal Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; A. Parkinson, Patient Research Partner; W. Campbell, BEd, LLB, Patient Research Partner, Toronto Western Hospital; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust.</nlm:affiliation></affiliation></author><author><name sortKey="Gossec, Laure" sort="Gossec, Laure" uniqKey="Gossec L" first="Laure" last="Gossec">Laure Gossec</name><affiliation><nlm:affiliation>From the Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK; VU Medical Centre, Amsterdam, The Netherlands; Toronto Western Hospital, Toronto, Ontario, Canada; PsAZZ Psoriatic Arthritis Support Group, Bath, UK; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.A.R. Moverley, MRCP, Research Fellow, Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; R. Waxman, MPH, Research Coordinator, Leeds Institute of Rheumatic and Musculoskeletal Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; A. Parkinson, Patient Research Partner; W. Campbell, BEd, LLB, Patient Research Partner, Toronto Western Hospital; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust.</nlm:affiliation></affiliation></author><author><name sortKey="Helliwell, Philip S" sort="Helliwell, Philip S" uniqKey="Helliwell P" first="Philip S" last="Helliwell">Philip S. Helliwell</name><affiliation><nlm:affiliation>From the Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK; VU Medical Centre, Amsterdam, The Netherlands; Toronto Western Hospital, Toronto, Ontario, Canada; PsAZZ Psoriatic Arthritis Support Group, Bath, UK; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.A.R. Moverley, MRCP, Research Fellow, Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; R. Waxman, MPH, Research Coordinator, Leeds Institute of Rheumatic and Musculoskeletal Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; A. Parkinson, Patient Research Partner; W. Campbell, BEd, LLB, Patient Research Partner, Toronto Western Hospital; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust. p.helliwell@leeds.ac.uk.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27134273</idno><idno type="pmid">27134273</idno><idno type="doi">10.3899/jrheum.160118</idno><idno type="wicri:Area/PubMed/Corpus">000148</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000148</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Development of a Flare Instrument for Use in Psoriatic Disease: A Report from the 2015 GRAPPA Annual Meeting.</title><author><name sortKey="Moverley, Anna R" sort="Moverley, Anna R" uniqKey="Moverley A" first="Anna R" last="Moverley">Anna R. Moverley</name><affiliation><nlm:affiliation>From the Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK; VU Medical Centre, Amsterdam, The Netherlands; Toronto Western Hospital, Toronto, Ontario, Canada; PsAZZ Psoriatic Arthritis Support Group, Bath, UK; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.A.R. Moverley, MRCP, Research Fellow, Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; R. Waxman, MPH, Research Coordinator, Leeds Institute of Rheumatic and Musculoskeletal Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; A. Parkinson, Patient Research Partner; W. Campbell, BEd, LLB, Patient Research Partner, Toronto Western Hospital; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust.</nlm:affiliation></affiliation></author><author><name sortKey="Waxman, Robin" sort="Waxman, Robin" uniqKey="Waxman R" first="Robin" last="Waxman">Robin Waxman</name><affiliation><nlm:affiliation>From the Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK; VU Medical Centre, Amsterdam, The Netherlands; Toronto Western Hospital, Toronto, Ontario, Canada; PsAZZ Psoriatic Arthritis Support Group, Bath, UK; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.A.R. Moverley, MRCP, Research Fellow, Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; R. Waxman, MPH, Research Coordinator, Leeds Institute of Rheumatic and Musculoskeletal Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; A. Parkinson, Patient Research Partner; W. Campbell, BEd, LLB, Patient Research Partner, Toronto Western Hospital; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust.</nlm:affiliation></affiliation></author><author><name sortKey="De Wit, Maarten" sort="De Wit, Maarten" uniqKey="De Wit M" first="Maarten" last="De Wit">Maarten De Wit</name><affiliation><nlm:affiliation>From the Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK; VU Medical Centre, Amsterdam, The Netherlands; Toronto Western Hospital, Toronto, Ontario, Canada; PsAZZ Psoriatic Arthritis Support Group, Bath, UK; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.A.R. Moverley, MRCP, Research Fellow, Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; R. Waxman, MPH, Research Coordinator, Leeds Institute of Rheumatic and Musculoskeletal Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; A. Parkinson, Patient Research Partner; W. Campbell, BEd, LLB, Patient Research Partner, Toronto Western Hospital; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust.</nlm:affiliation></affiliation></author><author><name sortKey="Parkinson, Andrew" sort="Parkinson, Andrew" uniqKey="Parkinson A" first="Andrew" last="Parkinson">Andrew Parkinson</name><affiliation><nlm:affiliation>From the Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK; VU Medical Centre, Amsterdam, The Netherlands; Toronto Western Hospital, Toronto, Ontario, Canada; PsAZZ Psoriatic Arthritis Support Group, Bath, UK; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.A.R. Moverley, MRCP, Research Fellow, Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; R. Waxman, MPH, Research Coordinator, Leeds Institute of Rheumatic and Musculoskeletal Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; A. Parkinson, Patient Research Partner; W. Campbell, BEd, LLB, Patient Research Partner, Toronto Western Hospital; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust.</nlm:affiliation></affiliation></author><author><name sortKey="Campbell, Willemina" sort="Campbell, Willemina" uniqKey="Campbell W" first="Willemina" last="Campbell">Willemina Campbell</name><affiliation><nlm:affiliation>From the Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK; VU Medical Centre, Amsterdam, The Netherlands; Toronto Western Hospital, Toronto, Ontario, Canada; PsAZZ Psoriatic Arthritis Support Group, Bath, UK; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.A.R. Moverley, MRCP, Research Fellow, Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; R. Waxman, MPH, Research Coordinator, Leeds Institute of Rheumatic and Musculoskeletal Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; A. Parkinson, Patient Research Partner; W. Campbell, BEd, LLB, Patient Research Partner, Toronto Western Hospital; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust.</nlm:affiliation></affiliation></author><author><name sortKey="Brooke, Melanie" sort="Brooke, Melanie" uniqKey="Brooke M" first="Melanie" last="Brooke">Melanie Brooke</name><affiliation><nlm:affiliation>From the Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK; VU Medical Centre, Amsterdam, The Netherlands; Toronto Western Hospital, Toronto, Ontario, Canada; PsAZZ Psoriatic Arthritis Support Group, Bath, UK; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.A.R. Moverley, MRCP, Research Fellow, Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; R. Waxman, MPH, Research Coordinator, Leeds Institute of Rheumatic and Musculoskeletal Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; A. Parkinson, Patient Research Partner; W. Campbell, BEd, LLB, Patient Research Partner, Toronto Western Hospital; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust.</nlm:affiliation></affiliation></author><author><name sortKey="Gossec, Laure" sort="Gossec, Laure" uniqKey="Gossec L" first="Laure" last="Gossec">Laure Gossec</name><affiliation><nlm:affiliation>From the Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK; VU Medical Centre, Amsterdam, The Netherlands; Toronto Western Hospital, Toronto, Ontario, Canada; PsAZZ Psoriatic Arthritis Support Group, Bath, UK; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.A.R. Moverley, MRCP, Research Fellow, Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; R. Waxman, MPH, Research Coordinator, Leeds Institute of Rheumatic and Musculoskeletal Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; A. Parkinson, Patient Research Partner; W. Campbell, BEd, LLB, Patient Research Partner, Toronto Western Hospital; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust.</nlm:affiliation></affiliation></author><author><name sortKey="Helliwell, Philip S" sort="Helliwell, Philip S" uniqKey="Helliwell P" first="Philip S" last="Helliwell">Philip S. Helliwell</name><affiliation><nlm:affiliation>From the Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK; VU Medical Centre, Amsterdam, The Netherlands; Toronto Western Hospital, Toronto, Ontario, Canada; PsAZZ Psoriatic Arthritis Support Group, Bath, UK; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.A.R. Moverley, MRCP, Research Fellow, Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; R. Waxman, MPH, Research Coordinator, Leeds Institute of Rheumatic and Musculoskeletal Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; A. Parkinson, Patient Research Partner; W. Campbell, BEd, LLB, Patient Research Partner, Toronto Western Hospital; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust. p.helliwell@leeds.ac.uk.</nlm:affiliation></affiliation></author></analytic><series><title level="j">The Journal of rheumatology</title><idno type="ISSN">0315-162X</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) initiative is to develop a questionnaire to determine the presence of a flare of disease activity in psoriatic disease (PsD), for use in clinical care and research settings.</div></front></TEI><pubmed><MedlineCitation Status="In-Data-Review" Owner="NLM"><PMID Version="1">27134273</PMID><DateCreated><Year>2016</Year><Month>05</Month><Day>02</Day></DateCreated><DateRevised><Year>2016</Year><Month>05</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0315-162X</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>May</Month></PubDate></JournalIssue><Title>The Journal of rheumatology</Title><ISOAbbreviation>J. Rheumatol.</ISOAbbreviation></Journal><ArticleTitle>Development of a Flare Instrument for Use in Psoriatic Disease: A Report from the 2015 GRAPPA Annual Meeting.</ArticleTitle><Pagination><MedlinePgn>974-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3899/jrheum.160118</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective of this Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) initiative is to develop a questionnaire to determine the presence of a flare of disease activity in psoriatic disease (PsD), for use in clinical care and research settings.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In 2014 and 2015, 2 online Delphi surveys of patients and physicians attempted to achieve consensus about items that might discriminate a flare of disease. In the first round, items were derived from previous qualitative studies with patients; in the second round, new items, suggested by both patients and physicians, were added. Survey results were discussed at the 2015 GRAPPA annual meeting, and 8 breakout groups discussed specific aspects of PsD flares.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Survey participants were patients (n = 103 and n = 57 in rounds 1 and 2) and physicians (n = 125 and n = 81). Items for flare covered 6 domains (joints, skin, emotion, participation, fatigue, and unclassified). Patients agreed that 20 items were important (10 joints, 1 participation, 8 fatigue, 1 unclassified), and physicians agreed on 23 items (5 skin, 11 joints, 4 participation, 3 unclassified). Eight items were selected as important by both groups: 7 joint items and 1 unclassified. Patients emphasized fatigue and physicians emphasized skin and participation. Breakout groups concluded that the components of a flare instrument should be derived from patients. A flare should be defined as a change in disease state requiring intervention.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The concept of flare in PsD covers articular, skin, emotional, participation, and fatigue domains. Further work is required to specify items that represent these domains.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moverley</LastName><ForeName>Anna R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>From the Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK; VU Medical Centre, Amsterdam, The Netherlands; Toronto Western Hospital, Toronto, Ontario, Canada; PsAZZ Psoriatic Arthritis Support Group, Bath, UK; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.A.R. Moverley, MRCP, Research Fellow, Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; R. Waxman, MPH, Research Coordinator, Leeds Institute of Rheumatic and Musculoskeletal Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; A. Parkinson, Patient Research Partner; W. Campbell, BEd, LLB, Patient Research Partner, Toronto Western Hospital; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waxman</LastName><ForeName>Robin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK; VU Medical Centre, Amsterdam, The Netherlands; Toronto Western Hospital, Toronto, Ontario, Canada; PsAZZ Psoriatic Arthritis Support Group, Bath, UK; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.A.R. Moverley, MRCP, Research Fellow, Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; R. Waxman, MPH, Research Coordinator, Leeds Institute of Rheumatic and Musculoskeletal Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; A. Parkinson, Patient Research Partner; W. Campbell, BEd, LLB, Patient Research Partner, Toronto Western Hospital; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Wit</LastName><ForeName>Maarten</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK; VU Medical Centre, Amsterdam, The Netherlands; Toronto Western Hospital, Toronto, Ontario, Canada; PsAZZ Psoriatic Arthritis Support Group, Bath, UK; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.A.R. Moverley, MRCP, Research Fellow, Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; R. Waxman, MPH, Research Coordinator, Leeds Institute of Rheumatic and Musculoskeletal Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; A. Parkinson, Patient Research Partner; W. Campbell, BEd, LLB, Patient Research Partner, Toronto Western Hospital; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parkinson</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK; VU Medical Centre, Amsterdam, The Netherlands; Toronto Western Hospital, Toronto, Ontario, Canada; PsAZZ Psoriatic Arthritis Support Group, Bath, UK; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.A.R. Moverley, MRCP, Research Fellow, Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; R. Waxman, MPH, Research Coordinator, Leeds Institute of Rheumatic and Musculoskeletal Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; A. Parkinson, Patient Research Partner; W. Campbell, BEd, LLB, Patient Research Partner, Toronto Western Hospital; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>Willemina</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>From the Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK; VU Medical Centre, Amsterdam, The Netherlands; Toronto Western Hospital, Toronto, Ontario, Canada; PsAZZ Psoriatic Arthritis Support Group, Bath, UK; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.A.R. Moverley, MRCP, Research Fellow, Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; R. Waxman, MPH, Research Coordinator, Leeds Institute of Rheumatic and Musculoskeletal Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; A. Parkinson, Patient Research Partner; W. Campbell, BEd, LLB, Patient Research Partner, Toronto Western Hospital; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooke</LastName><ForeName>Melanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK; VU Medical Centre, Amsterdam, The Netherlands; Toronto Western Hospital, Toronto, Ontario, Canada; PsAZZ Psoriatic Arthritis Support Group, Bath, UK; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.A.R. Moverley, MRCP, Research Fellow, Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; R. Waxman, MPH, Research Coordinator, Leeds Institute of Rheumatic and Musculoskeletal Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; A. Parkinson, Patient Research Partner; W. Campbell, BEd, LLB, Patient Research Partner, Toronto Western Hospital; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gossec</LastName><ForeName>Laure</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK; VU Medical Centre, Amsterdam, The Netherlands; Toronto Western Hospital, Toronto, Ontario, Canada; PsAZZ Psoriatic Arthritis Support Group, Bath, UK; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.A.R. Moverley, MRCP, Research Fellow, Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; R. Waxman, MPH, Research Coordinator, Leeds Institute of Rheumatic and Musculoskeletal Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; A. Parkinson, Patient Research Partner; W. Campbell, BEd, LLB, Patient Research Partner, Toronto Western Hospital; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helliwell</LastName><ForeName>Philip S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>From the Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK; VU Medical Centre, Amsterdam, The Netherlands; Toronto Western Hospital, Toronto, Ontario, Canada; PsAZZ Psoriatic Arthritis Support Group, Bath, UK; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.A.R. Moverley, MRCP, Research Fellow, Clinical Trials Research Unit, Leeds Institute of Molecular Medicine, University of Leeds; R. Waxman, MPH, Research Coordinator, Leeds Institute of Rheumatic and Musculoskeletal Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; A. Parkinson, Patient Research Partner; W. Campbell, BEd, LLB, Patient Research Partner, Toronto Western Hospital; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust. p.helliwell@leeds.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>J Rheumatol</MedlineTA><NlmUniqueID>7501984</NlmUniqueID><ISSNLinking>0315-162X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DISEASE FLARE</Keyword><Keyword MajorTopicYN="N">GRAPPA</Keyword><Keyword MajorTopicYN="N">PSORIASIS</Keyword><Keyword MajorTopicYN="N">PSORIATIC ARTHRITIS</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27134273</ArticleId><ArticleId IdType="pii">43/5/974</ArticleId><ArticleId IdType="doi">10.3899/jrheum.160118</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000148 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000148 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27134273
|texte= Development of a Flare Instrument for Use in Psoriatic Disease: A Report from the 2015 GRAPPA Annual Meeting.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27134273" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |